stoxline Quote Chart Rank Option Currency Glossary
X4 Pharmaceuticals, Inc. (XFOR)
0.9015  0.044 (5.18%)    12-07 16:00
Open: 0.8448
High: 0.9083
Volume: 1,846,368
Pre. Close: 0.8571
Low: 0.8233
Market Cap: 151(M)
Technical analysis
2023-12-07 4:24:20 PM
Short term     
Mid term     
Targets 6-month :  1.12 1-year :  1.3
Resists First :  0.95 Second :  1.12
Pivot price 0.8
Supports First :  0.8 Second :  0.7
MAs MA(5) :  0.84 MA(20) :  0.79
MA(100) :  1.1 MA(250) :  1.24
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  79.9 D(3) :  75.1
RSI RSI(14): 57.7
52-week High :  2.57 Low :  0.64
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ XFOR ] has closed above the upper band by 2.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 41.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.91 - 0.91 0.91 - 0.92
Low: 0.81 - 0.82 0.82 - 0.82
Close: 0.89 - 0.9 0.9 - 0.91
Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Headline News

Mon, 04 Dec 2023
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Fri, 10 Nov 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 09 Nov 2023
X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate Progress - Yahoo Finance

Thu, 09 Nov 2023
X4 Pharmaceuticals: Q3 Earnings Snapshot - Quartz

Mon, 06 Nov 2023
X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares (NASDAQ:XFOR) - Seeking Alpha

Mon, 06 Nov 2023
After losing 47% in the past year, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) institutional owners must be relieved by the recent gain - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 167 (M)
Shares Float 135 (M)
Held by Insiders 0.8 (%)
Held by Institutions 68.6 (%)
Shares Short 11,450 (K)
Shares Short P.Month 10,880 (K)
Stock Financials
EPS -0.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.4
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -47.1 %
Return on Equity (ttm) -171.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.65
Qtrly Earnings Growth 0 %
Operating Cash Flow -88 (M)
Levered Free Cash Flow -51 (M)
Stock Valuations
PE Ratio -1.33
PEG Ratio 0
Price to Book value 2.19
Price to Sales 0
Price to Cash Flow -1.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android